106 related articles for article (PubMed ID: 21671827)
1. AFCo1 as nasal adjuvant of capsular polysaccharide from Neisseria meningitidis serogroup C induces systemic and mucosal immune responses.
Romeu B; González E; Zayas C; Del Campo J; Acevedo R; Cuello M; Valdes Y; Balboa J; Cabrera O; Lastre M; Pérez O
Scand J Infect Dis; 2011 Oct; 43(10):809-13. PubMed ID: 21671827
[TBL] [Abstract][Full Text] [Related]
2. Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses.
Campo JD; Zayas C; Romeu B; Acevedo R; González E; Bracho G; Cuello M; Cabrera O; Balboa J; Lastre M
Methods; 2009 Dec; 49(4):301-8. PubMed ID: 19410000
[TBL] [Abstract][Full Text] [Related]
3. Pilot scale production of the vaccine adjuvant Proteoliposome derived Cochleates (AFCo1) from Neisseria meningitidis serogroup B.
Zayas C; González D; Acevedo R; del Campo J; Lastre M; González E; Romeu B; Cuello M; Balboa J; Cabrera O; Guilherme L; Pérez O
BMC Immunol; 2013; 14 Suppl 1(Suppl 1):S4. PubMed ID: 23458578
[TBL] [Abstract][Full Text] [Related]
4. Mucosal and systemic immune responses of mice to tetanus toxoid coadministered nasally with AFCo1.
Romeu B; González E; Del Campo J; Acevedo R; Zayas C; Valdés Y; Cabrera O; Cuello M; Balboa J; Lastre M; Pérez O
Can J Microbiol; 2011 Mar; 57(3):256-61. PubMed ID: 21358768
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice.
Fukasawa LO; Dias WO; Schenkman RP; Raw I; Tanizaki MM
FEMS Immunol Med Microbiol; 2004 Jul; 41(3):205-10. PubMed ID: 15196569
[TBL] [Abstract][Full Text] [Related]
6. New vaccines require potent adjuvants like AFPL1 and AFCo1.
Pérez O; Lastre M; Cabrera O; del Campo J; Bracho G; Cuello M; Balboa J; Acevedo R; Zayas C; Gil D; Mora N; González D; Pérez R; González E; Barberá R; Fajardo EM; Sierra G; Solís RL; Campa C
Scand J Immunol; 2007; 66(2-3):271-7. PubMed ID: 17635804
[TBL] [Abstract][Full Text] [Related]
7. Two different methods result in the selection of peptides that induce a protective antibody response to Neisseria meningitidis serogroup C.
Prinz DM; Smithson SL; Westerink MA
J Immunol Methods; 2004 Feb; 285(1):1-14. PubMed ID: 14871530
[TBL] [Abstract][Full Text] [Related]
8. New meningococcal C polysaccharide-tetanus toxoid conjugate Physico-chemical and immunological characterization.
Cuello M; Cabrera O; Martinez I; Del Campo JM; Camaraza MA; Sotolongo F; Pérez O; Sierra G
Vaccine; 2007 Feb; 25(10):1798-805. PubMed ID: 17240485
[TBL] [Abstract][Full Text] [Related]
9. Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis.
Zhu D; Barniak V; Zhang Y; Green B; Zlotnick G
Vaccine; 2006 Jun; 24(26):5420-5. PubMed ID: 16621173
[TBL] [Abstract][Full Text] [Related]
10. Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide.
Prinz DM; Smithson SL; Kieber-Emmons T; Westerink MA
Immunology; 2003 Oct; 110(2):242-9. PubMed ID: 14511238
[TBL] [Abstract][Full Text] [Related]
11. New proteoliposome vaccine formulation from N. meningitidis serogroup B, without aluminum hydroxide, retains its antimeningococcal protectogenic potential as well as Th-1 adjuvant capacity.
Tamargo B; Márquez Y; Ramírez W; Cedré B; Fresno M; Sierra G
BMC Immunol; 2013; 14 Suppl 1(Suppl 1):S12. PubMed ID: 23458443
[TBL] [Abstract][Full Text] [Related]
12. Intranasal immunization of mice with recombinant Streptococcus gordonii expressing NadA of Neisseria meningitidis induces systemic bactericidal antibodies and local IgA.
Ciabattini A; Giomarelli B; Parigi R; Chiavolini D; Pettini E; Aricò B; Giuliani MM; Santini L; Medaglini D; Pozzi G
Vaccine; 2008 Aug; 26(33):4244-50. PubMed ID: 18582996
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of immunological responses to recombinant Porin A protein (rPoA) from native strains of Neisseria meningitidis serogroups A and B using OMV as an adjuvant in BALB/c mice.
Afrough P; Bouzari S; Mousavi SF; Asadi Karam MR; Vaziri F; Fateh A; Behrouzi A; Malekan M; Siadat SD
Microb Pathog; 2017 Nov; 112():209-214. PubMed ID: 28942175
[TBL] [Abstract][Full Text] [Related]
14. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
Patel GB; Zhou H; Ponce A; Chen W
Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
[TBL] [Abstract][Full Text] [Related]
15. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of immune responses to nasal challenge with meningococcal polysaccharide one year after serogroup-C glycoconjugate vaccination.
Wing JB; Smart L; Borrow R; Findlow J; Findlow H; Heath AW; Read RC
Clin Infect Dis; 2011 Jun; 52(11):1317-23. PubMed ID: 21596673
[TBL] [Abstract][Full Text] [Related]
17. Comparison of three ELISA protocols to measure antibody responses elicited against serogroup C meningococcal polysaccharide in mouse, monkey and human sera.
Guirola M; Carmenate T; Menéndez T; Alvarez A; González S; Guillén G
J Microbiol Methods; 2006 Apr; 65(1):135-43. PubMed ID: 16122825
[TBL] [Abstract][Full Text] [Related]
18. AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5.
Bracho G; Zayas C; Wang L; Coppel R; Pérez O; Petrovsky N
Malar J; 2009 Feb; 8():35. PubMed ID: 19250541
[TBL] [Abstract][Full Text] [Related]
19. Combined Haemophilus Influenzae type B-Neisseria meningitidis serogroup C vaccine is immunogenic and well tolerated in preterm infants when coadministered with other routinely recommended vaccines.
Omeñaca F; Arístegui J; Tejedor JC; Moreno-Perez D; Ruiz-Contreras J; Merino JM; Muro Brussi M; Sánchez-Tamayo T; Castro Fernandez J; Cabanillas L; Peddiraju K; Mesaros N; Miller JM
Pediatr Infect Dis J; 2011 Nov; 30(11):e216-24. PubMed ID: 21747321
[TBL] [Abstract][Full Text] [Related]
20. Towards a nasal vaccine against meningococcal disease, and prospects for its use as a mucosal adjuvant.
Haneberg B; Dalseg R; Oftung F; Wedege E; Høiby EA; Haugen IL; Holst J; Andersen SR; Aase A; Meyer Naess L; Michaelsen TE; Namork E; Haaheim LR
Dev Biol Stand; 1998; 92():127-33. PubMed ID: 9554266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
